About

From Benchtop to Clinical Trial: Examples of technology development: Presenters will describe a technology that has gone from benchtop development and pre-clinical evaluation to being studied in a recent clinical trial, in order to provide the audience with perspective on the development process through specific examples with supporting data. Presenters from industry, academia/healthcare settings and regulatory agencies are all encouraged to submit. Talks will be of extended duration and may be presented by a single speaker or two speakers (a scientist/engineer and a clinician to separately present the pre-clinical and clinical outcomes). Selection preference will be given to abstracts that best illustrate the medical device development pipeline through a specific detailed example.

Abstracts

10:30 a.m. Topical introduction by the moderators
10:45 a.m. 274. The Development of a Superior Decellularized Human Dermal Product for Advanced Wound Care, P. F. Gratzer*(1), M. Glazebrook(2), K. Conlan(1), (1)Dalhousie University, Halifax, NS, (2)Queen Elizabeth II Hospital, Halifax, NS
11:00 a.m. 275. From Benchtop to Clinical Trial – Exogenous Crosslinking To Treat Disc Degeneration and Low Back Pain, T. Hedman*(1), M. Brown(1), J. Racadio(2), H. Singh(3), (1)Intralink Spine, Inc., Lexington, KY, (2)Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (3)Pantai Medical Centre, Kuala Lumpur, Malaysia
11:15 a.m. 276. Biomaterials as Medicine: Successful Treatment of Human MRSA Bacteremia with a Sorbent Hemoperfusion Device, R. S. Ward*, K. A. White, K. McCrea, ExThera Medical Corporation, Martinez, CA
11:30 a.m. 277. Tissue Remodeling of a Resorbable Poly-4-hydroxybutyrate Scaffold for Soft Tissue Repair, D. P. Martin*, E. Diaz Santiago, A. Ganatra, K. Guo, Tepha, Inc., Lexington, MA
11:45 a.m. 278. Q & A Session

Panel Discussion: Preventing Implant-Associated Infection

About

The consequences of implant-associated infection are significant and often results in the “failure” of the surgical procedure. Various approaches are being proposed and studied to reduce the rate of infection including coating implants with antimicrobial materials or antibiotics; covalently attaching antimicrobial molecules onto the implant surface; and utilizing controlled release nanoparticles. The purpose of this panel discussion is to provide the background, the new approaches, and the challenges for reducing implant-associated infections. Leaders of the field, including several past SFB Presidents, will present the different perspectives of clinicians, basic scientists & engineers, and industry.

Invited Speaker(s)

Stuart Goodman, MD, PhD
Frederick J. Schoen, MD, PhD
David Armbruster, PhD
Dustin Williams, PhD

3rd Business Plan Competition

About

3rd SFB Business Plan Competition: Students and post docs: Medical technology requires more than just laboratory results to become a reality. Do you believe that your biomaterials-based research innovation has the potential to succeed in the medical device industry? Put your skills to the test in this unique session designed to challenge you to consider the commercialization aspects of your research. Individuals and groups (your choice) will be judged by experts from investing, industry, regulatory, and academia on the strength of their commercialization plans. Prizes will be awarded to the top teams, including audience’s choice. To participate, submit an abstract that contains your Executive Summary, including information on your technology, the market, and the commercialization strategy. Those selected will give a 10 minute pitch followed by Q&A “Shark Tank” style from judges and audience.

Abstracts

10:30 a.m. 279. ,
10:38 a.m. 280. HydrUStent – Biodegradable Ureteral Stent, A. Barros*(1), C. Oliveira(2), R. Reis(3), E. Lima(4), A. R. Duarte(3), (1)3Bs Research Group, Guimaraes, Portugal, (2)Life and Health Sciences Research Institute, Braga, Portugal, (3)3Bs research Group, University of Minho, Guimaraes, Portugal, (4)ICVS,
10:50 a.m. 281. LaunchPad Medical, LLC, F. Prifti*(1), B. Hess(2), G. Kay(2), D. G. Allen(2), D. W. Van Citters(1), (1)Dartmouth College, Hanover, NH, (2)LaunchPad Medical, LLC, Boston, MA
11:02 a.m. 282. 20/20 OptimEyes: Drug Delivery Solutions to Improve Ocular Health, B. Muirhead, H. Sheardown, McMaster University, Hamilton, ON
11:14 a.m. 283. Tech Wound Solutions: Kare Powder Chronic Wound Dressing, T. King*, J. Downey, E. Rebholz, M. Thompson, K. Wyluda, Virginia Tech, Blacksburg, VA
11:26 a.m. 284. Neurogel; an injectable solution to peripheral nerve injury, T. Prest*, L. Soletti, B. Brown, University of Pittsburgh, Pittsburgh, PA
11:38 a.m. 285. The Rescue Stent for Non-Compressible Traumatic Hemorrhage, P. Shridhar*(1,2), B. Tillman(1,2), Y. Chen(1), S. K. Cho(1), Y. Chun(1,2), (1)University of Pittsburgh, Pittsburgh, PA, (2)University of Pittsburgh Medical Center, Pittsburgh, PA
11:50 a.m. 286. Voting and Awards

Biomaterial - Tissue Interaction

Abstracts

10:30 a.m. 287. Toll-like receptor 2-mediated NF-kB activation by damage-associated molecular patterns on biomaterial surfaces, L. A. McKiel, L. E. Fitzpatrick*, Queen's University, Kingston, ON
10:45 a.m. 288. Oxygen-controllable hydrogels for Engineered Tissue Models, S. Gerecht, Johns Hopkins University, Baltimore, MD
11:00 a.m. 289. Effects of Aging upon the Host Response to Biomaterials, B. N. Brown*, D. Hachim, N. Wang, S. LoPresti, E. Stahl, University of Pittsburgh, Pittsburgh, PA
11:15 a.m. 290. An Elastic, Precision-Engineered Porous Polyurethane Material Mitigates Foreign Body Capsule Formation and Promotes Tissue Integration In Vivo, L. Zhen*, S. A. Creason, B. D. Ratner, University of Washington, Seattle, WA
11:30 a.m. 291. Protease-Degradable Microgels for Protein Delivery for Vascularization, G. A. Foster*(1), D. M. Headen(1), C. González-García(2), M. Salmerón-Sánchez(2), H. Shirwan(3), A. J. García(1), (1)Georgia Institute of Technology, Atlanta, GA, (2)University of Glasgow, Glasgow, United Kingdom, (3)University of Louisville, Louisville,
11:45 a.m. 292. Direct transportation of polymer nanoparticles to the cell nucleus by surface decoration with multi-oligopeptides, K. Ishihara, Y. Tamagaki, Y. Inoue, The University of Tokyo, Tokyo, Japan

Engineering Materials and Delivery Systems for Modern Vaccines

About

Engineering Materials and Delivery Systems for Modern Vaccines: Modern vaccines are smartly engineered by integrating the knowledge from recent advancements in immune signaling, infectious diseases, material science and drug delivery technologies. The theme of this session would be catering the translational needs of modern vaccines using multi-disciplinary approaches involving unique biomaterials, formulations or delivery systems. The topics includes polymer technology, biologically active materials, nanotechnology, microneedles, and/or adjuvant-technologies for the application of vaccines.

Abstracts

10:30 a.m. 293. Invited Speaker: Mahesh Kumar, PhD
11:00 a.m. 295. Cationic Polymer-Based Stabilization Strategies for Single-Administration Inactivated Polio Vaccine, S. Y. Tzeng*, A. M. Behrens, S. Rose, S. Ferber, K. J. McHugh, R. S. Langer, A. Jaklenec, Massachusetts Institute of Technology, Cambridge, MA
11:15 a.m. 296. Adjuvant Free Peptide Nanofibers Elicit CD8+ T Cell Responses after Intranasal Administration, Y. Wen*(1), Y. Si(2), A. Chong(2), J. H. Collier(1), (1)Duke University, Durham, NC, (2)University of Chicago, Chicago, IL
11:30 a.m. 297. Binary Polymer Blends as Mucoadhesive Wafers for Sublingual Delivery of Protein Vaccines, S. Hanson*(1), S. Singh(2), J. K. Sastry(2), M. Barry(3), C. Wang(1), (1)University of Minneosta, Minneapolis, MN, (2)MD Anderson Cancer Center, Houston, TX, (3)Mayo Clinic, Rochester, MN
11:45 a.m. 298. Expansion of tumor-specific T Cells using Immune Polyelectrolyte Multilayers assembled on Microneedles, Q. Zeng*(1), J. Gammon(1), L. Tostanoski(1), C. Jewell(1,2), (1)University of Maryland-College Park, College Park, MD, (2)University of Maryland Medical School, Marlene and Stewart Greenebaum Cancer Center, US Dept of Veterans Affairs, College Park, MD

Invited Speaker(s)

Mahesh Kumar, PhD

Immunomodulation 3

Abstracts

10:30 a.m. 299. Expansion of Exhausted T Cell Populations via Electrospun Poly(Dimethyl Siloxane)-based Fibrous Meshes, A. Dang*(1), D. Bogdanowicz(1), S. M. Fernandes(2), J. R. Brown(2), H. H. Lu(1), L. C. Kam(1), (1)Columbia University, New York, NY, (2)Harvard Medical School, Boston, MA
10:45 a.m. 300. Self-assembly of Polyionic Immune Signals to Program Myelin-specific Tolerance, L. H. Tostanoski, C. M. Jewell*, University of Maryland, College Park, MD
11:00 a.m. 301. Ex Vivo Immune Organoids with Protein-Sequestering Nanoparticles Regulate Kinetics of B cell Differentiation, A. Purwada*, A. Singh, Cornell University, Ithaca, NY
11:15 a.m. 302. Targeted Extracellular Indoleamine 2,3-Dioxygenase Suppresses Immune Responses In Vitro and In Vivo, E. Bracho-Sanchez*, A. Hassanzadeh, K. Y. Koenders, A. Restuccia, M. M. Fettis, M. A. Wallet, G. A. Hudalla, B. G. Keselowsky, University of Florida, Gainesville, FL
11:30 a.m. 303. Amelioration of inflammation through daily infusion of unmodified poly (lactide-co-glycolide) particles, E. Saito*, R. Kuo, R. M. Pearson, N. Gohel, L. D. Shea, University of Michigan, Ann Arbor, MI
11:45 a.m. 304. Alpha-helical peptide nanofibers as non-inflammatory self-adjuvanting vaccines, Y. Wu*, J. H. Collier, Duke, Durham, NC

Regeneration of Craniomaxillofacial Tissue

Abstracts

10:30 a.m. 311. Effect of ECM Source Tissue on Remodeling of TMJ Meniscus Replacement Device, S. T. LoPresti*, J. Lowe, W. J. Chung, S. F. Badylak, A. J. Almarza, B. N. Brown, University of Pittsburgh, Pittsburgh, PA
10:45 a.m. 312. Culturing TgfbR2 Expressing Progenitor Cells on Textile Scaffolds Fabricated from Resorbable PLLA for Regeneration of Tendon-Bone Junction, H. Ramakrishna*(1), T. He(1), T. Li(2), M. W. King(1), A. Spagnoli(2), (1)North Carolina State University, Raleigh, NC, (2)Rush University Medical Center, Chicago, IL
11:00 a.m. 313. A Fast-degrading Thiol-acrylate Hydrogel as a Cell Carrier for Craniofacial Bone Regeneration, A. M. Emmakah(1), M. B. Alvarez(2), P. Childress(2), W. S. Goebel(3), M. A. Kacena(2), C.-C. Lin(1,4), T.-M. G. Chu*(5), (1)Purdue University, Indianapolis, IN, (2)Indiana University School of Medicine, Indianapolis, IN, (3)Riley Hospital for Children, In
11:15 a.m. 314. Material design controlling osteoclastic biodegradation and subsequent bone formation utilizing bioactive octacalcium phosphate crystals, O. Suzuki*, K. Saito, T. Anada, Y. Shiwaku, K. Tsuchiya, N. Miyatake, Tohoku University Graduate School of Dentistry, Sendai, Japan
11:30 a.m. 315. Heated Blood Plasma and Serum – A New Shifting Approach for Preparation of Barrier membrane and Bone-graft replacing material in the Guide Tissue Regeneration in Dentistry, J. Fidoski*(1), A. Stamatoski(2), (1)The Saints Cyril and Methodius University of Skopje, Skopje, FYRO Macedonia., Skopje, The former Yugoslav Republic of Macedonia, (2)The Saints Cyril and Methodius University of Skopje, Skopje, FYRO Macedonia., Tetovo,
11:45 a.m. 316. Development of a Self-Expanding Patch for Fetoscopic Myelomeningocele Repair, R. R. Tatu*(1), M. Oria(2), J. L. Peiro(2), C.-Y. Lin(1), (1)University of Cincinnati, Cincinnati, OH, (2)Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Thought Leader Symposium - Molly Shoichet, PhD: Overcoming Barriers to Neural Regeneration

About

In this symposium we will focus on key barriers to regeneration, including cell survival and cell integration, highlighting the role of biomaterials in overcoming some of these barriers.

Abstracts

Shelly Sakiyama-Elbert (University of Texas, Austin): "Using biomaterials to promote pro-regenerative glia phenotypes after nerve injury"
Hai-Quan Mao (Johns Hopkins): “Transcription Activation and Angiogenic Support to Enhance Survival and Differentiation of Neural Stem Cells for Brain Tissue Regeneration”
Jeff Sakamoto (University of Michigan): "Neural regeneration implant design, material selection, and manufacturing”
Tatiana Segura (University of California, Los Angeles): "Repairing the stroked brain: overcoming barriers to repair using hydrogel biomaterials"

*BTI* From Benchtop to Clinical Trial: Examples of Technology Development

About

Abstracts

Panel Discussion: Preventing Implant-Associated Infection

About

Abstracts

Invited Speaker(s)

3rd Business Plan Competition

About

Abstracts

Biomaterial - Tissue Interaction

Abstracts

Engineering Materials and Delivery Systems for Modern Vaccines

About

Abstracts

Invited Speaker(s)

Immunomodulation 3

Abstracts

Regeneration of Craniomaxillofacial Tissue

Abstracts

Thought Leader Symposium - Molly Shoichet, PhD: Overcoming Barriers to Neural Regeneration

About

Abstracts

Invited Speaker(s)

BTI From Benchtop to Clinical Trial: Examples of Technology Development